David Apelian - Aug 16, 2022 Form 4 Insider Report for Eiger BioPharmaceuticals, Inc. (EIGR)

Role: Director
Signature: /s/ Sriram Ryali, Attorney-in-Fact
Stock symbol: EIGR
Transactions as of: Aug 16, 2022
Transactions value $: -$49,031
Form type: 4
Date filed: 8/18/2022, 05:36 PM
Previous filing: Mar 11, 2022
Next filing: Feb 2, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EIGR	Common Stock	Sale	-$49K	-5K	-31.25%	$9.81	11K	Aug 16, 2022	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 13, 2022.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.80 to $ $9.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Content

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 13, 2022.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.80 to $ $9.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.